Finance
Bioenvision reports loss of $0.20 per share
Published in Drug Week, June 16th, 2006
"We continue to make progress developing our product portfolio, with Evoltra (clofarabine), Modrenal and Suvus, which may become significant value drivers for the company in the future," commented Christopher B. Wood, MD, chairman and CEO of Bioenvision. "We are delighted especially with the CHMP Positive Opinion in the E.U.'s centralized process and look forward to our European marketing launch of Evoltra in the near future.
"We hope to continue the Evoltra development process with a filing for approval with the EMeA in H2 2006 in elderly patients with AML who...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-06-16)
More Articles from Drug Week
- Cardiology
Acadesine reduces 2-year mortality following heart attacks in heart bypass patients - Drug Development
Acologix presents preclinical data on synthetic peptide - Drug Development
Axonyx completes multiple-dose phase I study of Posiphen - HIV/AIDS Drug Development
HIV-1 CD4 attachment inhibitor inhibits viral entry by altering envelope conformation - Sexual & Reproductive Health
ImQuest: Pyrimidinedione appears to prevent HIV transmission - Addiction Medicine
Bivalent morphine/heroin vaccine prevents relapse to heroin addiction - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
